Integril 0.7575mg/100ml

• Acute Coronary Syndrome (Unstable Angina/NSTEMI): Indicated for patients to be managed medically and those undergoing PCI.
• Percutaneous Coronary Intervention (PCI): Indicated for patients undergoing PCI, including those undergoing intracoronary stenting.

Adult Dose (Normal Renal Function):

• Acute Coronary Syndrome: 180 mcg/kg IV bolus, THEN 2 mcg/kg/min IV infusion for up to 72 hr.
• PCI: 180 mcg/kg IV bolus (before procedure), THEN 2 mcg/kg/min IV infusion; second 180 mcg/kg IV bolus 10 min after first.

Renal Dose (CrCl <50 mL/min):

• ACS: 180 mcg/kg IV bolus, THEN 1 mcg/kg/min IV infusion.
• PCI: 180 mcg/kg IV bolus, THEN 1 mcg/kg/min IV infusion; second 180 mcg/kg IV bolus 10 min after first.

Common Side Effects:

• Bleeding (mostly at femoral artery access site)
• Decreased blood pressure
• Intracranial hemorrhage and stroke (rare)
• Thrombocytopenia
• Allergic reactions

Precautions:

• Eptifibatide is intended for use in hospitalized patients.
• It is usually given by your nurse or doctor as an infusion (drip) into a vein.
• It increases your risk of bleeding. Be careful while shaving, cutting fingernails or toenails or using sharp objects.
• Notify your doctor if you see blood in your vomit, urine or stool.
• In patients undergoing PCI, there is an increase in bleeding at the site of arterial sheath placement.
• Caution in patients with platelet count <100,000/mm³.
• Avoid use with other GP IIb-IIIa inhibitors.